1. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy
- Author
-
Saryleine deOrtiz de Choudens, Alexis Visotcky, Anjishnu Banerjee, Mohammed Aldakkak, Susan Tsai, Douglas B. Evans, Kathleen K. Christians, Callisia N. Clarke, Ben George, Aditya Shreenivas, Mandana Kamgar, Sakti Chakrabarti, Kulwinder S. Dua, Abdul Haq Khan, Srivats Madhavan, Beth A. Erickson, and William A. Hall
- Subjects
neoplasm metastasis ,oligometastasis ,pancreatic neoplasms ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Purpose/Objectives Most patients with pancreatic adenocarcinoma (PDAC) will present with distant metastatic disease at diagnosis. We sought to identify clinical characteristics associated with prolonged overall survival (OS) in patients presenting with metastatic PDAC. Materials/Methods Patients presenting with metastatic PDAC that received treatment at our institution with FOLFIRINOX or gemcitabine‐based chemotherapies between August 1, 2011 and September 1, 2017 were included in the study. Metastatic disease burden was comprehensively characterized radiologically via individual diagnostic imaging segmentation. Landmark analysis was performed at 18 months, and survival curves were estimated using the Kaplan–Meier method and compared between groups via the log‐rank test. ECOG and Charlson Comorbidity Index (CCI) were calculated for all patients. Results 121 patients were included with a median age of 62 years (37–86), 40% were female, 25% had ECOG 0 at presentation. Of the 121 patients included, 33% (n = 41) were alive at 12 months and 25% (n = 31) were alive at 18 months. Landmark analysis demonstrated a significant difference between patients surviving 60 cc, p = 0.004), metastasis only in the liver (p = 0.04), and normalization of CA 19‐9 (p
- Published
- 2024
- Full Text
- View/download PDF